Alder BioPharmaceuticals Investor Presentation — May 2019

Zilucoplan, a Subcutaneously Self -Administered Peptide Inhibitor of Complement Component 5 (C5), for the Treatment of Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double -Blind, Placebo -Controlled Trial and Open -Label Long -Term Extension James F. Howard, Jr